Jan Lewis

Mr. Jan Lewis


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JLJan Lewis
Jan Lewis
IKIan Kerridge
Ian Kerridge
WLWendy Lipworth
Wendy Lipworth
Personalized medicines hold promise for many diseases. However, demonstrating the clinical efficacy and cost effectiveness of these medicines can be difficult. It is essential that decision-making processes for funding new medicines, including personalized medicines, are both robust and fit for purpose. We will argue that randomized trials of personalized medicines should be routinely supplemented with other research methods, such as observational research and single-arm studies, and that managed-entry funding programs, such as coverage with evidence development, may offer a means of providing early access to technologies where there is uncertainty about efficacy, safety, and cost effectiveness. These programs, however, raise a number of practical and ethical challenges that need to be worked through and resolved.

8 September 2014 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
JLJan Lewis
Jan Lewis
WLWendy Lipworth
Wendy Lipworth
IKI. Kerridge
I. Kerridge
EDE. Doran
E. Doran

Verified
Journal Article
Open access
PDF file
JLJan Lewis
Jan Lewis
WLWendy Lipworth
Wendy Lipworth
IKIan Kerridge
Ian Kerridge
Despite enthusiastic advocacy for what personalized medicine might be able to deliver and major investments into the development of this, there remain disappointingly few examples of personalized medicine in routine clinical practice today, particularly in high areas of unmet need such as cancer. We believe that this is because personalized medicine challenges the moral, economic and epistemological foundations of medicine. In this article, we briefly describe the scientific premises underpinning personalized medicine, contrast these with traditional paradigms of drug development, and then consider the ethical, economic and epistemological implications of this approach to medicine.

7 October 2013 in Medical Journal of Australia
Verified
Journal Article
Closed access
JLJan Lewis
Jan Lewis
WLWendy Lipworth
Wendy Lipworth
IKIan H Kerridge
Ian H Kerridge
RDRichard Day
Richard Day
Does the current evidence-based medicine model for assessing the clinical and cost-effectiveness of personalised therapies need revision?